TY - JOUR
T1 - Comparison of Two Cisplatin Regimens for Chemoradiation in Patients With Squamous-cell Carcinoma of the Head and Neck
AU - Zwaan, Inga
AU - Soror, Tamer
AU - Bruchhage, Karl L.
AU - Hakim, Samer G.
AU - Schild, Steven E.
AU - Rades, Dirk
N1 - Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
PY - 2023/2
Y1 - 2023/2
N2 - Background/Aim: Many patients with squamous-cell carcinoma of the head and neck receive cisplatin-based chemoradiation. This retrospective study compared two chemoradiation programs to help identify the optimal cisplatin-regimen. Patients and Methods: Forty-one patients assigned to chemoradiation with two cycles of 20 mg/m2/days(d)1-5 were compared to 78 patients assigned to chemoradiation with two cycles of 25 mg/m2/d1-4. Groups were compared for toxicity, loco-regional control (LRC), and survival. Results: Both treatments were associated with similar rates of oral mucositis, radiation dermatitis, xerostomia, nausea, decreased renal function, and hematotoxicity. The cisplatin-regimen had no significant impact on LRC (p=0.41) or survival (p=0.85). Survival was significantly worse with radiotherapy interruptions (>1 week) or discontinuation (p<0.001) and administration of <80% of the planned cisplatin dose (p<0.001). Conclusion: Both cisplatin-regimens did not differ significantly regarding toxicities, LRC, and survival. It is important to avoid interruption or discontinuation of radiotherapy and to administer ≥80% of planned cisplatin.
AB - Background/Aim: Many patients with squamous-cell carcinoma of the head and neck receive cisplatin-based chemoradiation. This retrospective study compared two chemoradiation programs to help identify the optimal cisplatin-regimen. Patients and Methods: Forty-one patients assigned to chemoradiation with two cycles of 20 mg/m2/days(d)1-5 were compared to 78 patients assigned to chemoradiation with two cycles of 25 mg/m2/d1-4. Groups were compared for toxicity, loco-regional control (LRC), and survival. Results: Both treatments were associated with similar rates of oral mucositis, radiation dermatitis, xerostomia, nausea, decreased renal function, and hematotoxicity. The cisplatin-regimen had no significant impact on LRC (p=0.41) or survival (p=0.85). Survival was significantly worse with radiotherapy interruptions (>1 week) or discontinuation (p<0.001) and administration of <80% of the planned cisplatin dose (p<0.001). Conclusion: Both cisplatin-regimens did not differ significantly regarding toxicities, LRC, and survival. It is important to avoid interruption or discontinuation of radiotherapy and to administer ≥80% of planned cisplatin.
UR - http://www.scopus.com/inward/record.url?scp=85146846349&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/4b56ffc0-24ad-3a09-ba3b-b9a6a95aabe9/
U2 - 10.21873/anticanres.16220
DO - 10.21873/anticanres.16220
M3 - Journal articles
C2 - 36697066
AN - SCOPUS:85146846349
SN - 0250-7005
VL - 43
SP - 795
EP - 800
JO - Anticancer Research
JF - Anticancer Research
IS - 2
ER -